Screener
Nurix Therapeutics, Inc. NRIX Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -982.4%-722pp | -439.3%-30.4pp | -340.2%+50.4pp | -319.3%+24.0pp | -260.8%+26.7pp | |
| Net margin | -928.4%-694pp | -411.4%-42.0pp | -314.9%+39.9pp | -292.5%+21.2pp | -234.6%+30.3pp | |
| Returns | ||||||
| Return on equity | -80.3%-29.6pp | -61.4%+2.8pp | -49.6%+3.6pp | -65.4%-7.4pp | -50.7%+1.7pp | |
| Return on invested capital | -89.5%-23.3pp | -70.2%+9.6pp | -72.2%-3.5pp | -81.8%-4.7pp | -66.2%+6.6pp | |
| Efficiency | ||||||
| Asset turnover | 0.1×-0.1× | 0.1×0.0× | 0.1×0.0× | 0.2×0.0× | 0.2×0.0× | |
| Liquidity | ||||||
| Current ratio | 6.3×-0.5× | 6×-0.3× | 7×+0.6× | 5.4×+0.1× | 6.8×+1.2× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.1×+0.1× | 0.1×0.0× | 0.2×+0.1× | 0.1×0.0× | |
| Per Share | ||||||
| Book value per share | $3.62-32.1% | $4.37-24.1% | $6.22-20.8% | $4.42-14.6% | $5.34-10.2% | |
| Valuation | ||||||
| Market capitalization | $2.62B+227% | $1.64B+40.1% | $1.79B+11.4% | $714.04M-61.1% | $744.82M-35.0% | |
| Price / sales | 71.2×+62.1× | 22.9×+2.1× | 21.3×-8.2× | 8.5×-24.0× | 8.4×-10.0× | |
| Price / book | 6.5×+4.7× | 3.4×+1.0× | 3.3×+0.3× | 1.9×-2.9× | 1.7×-1.4× |
FAQ
- Where do Nurix Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Nurix Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
